<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:9pt Arial, sans-serif; }
 .font1 { font:10pt Arial, sans-serif; }
 .font2 { font:15pt Times New Roman, serif; }
 .font3 { font:22pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font3">J.P. Morgan</span></p>
<p><span class="font1" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font1">07 September 2016</span></p>
<p><span class="font1">Isabella Y. Zhao, CFA</span></p>
<p><span class="font1">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.zhao@jpmorgan.com"><span class="font1">isabella.zhao@jpmorgan.com</span></a></p><a name="caption1"></a>
<h6><a name="bookmark0"></a><span class="font2" style="font-weight:bold;"><a name="bookmark1"></a>Retail pharmacy</span></h6>
<p><span class="font2">The Retail segment manages a network of drug stores in major Chinese cities via direct operation and franchises to sell pharmaceutical and healthcare products to endcustomers. The group operates a total of 68,264 in 2015 (61,761 in 2014).</span></p>
<p><span class="font2">Revenue from retail business was RMB 8,715 million, an Y-O-Y increase of 48%, and accounts for 3.81% of the overall revenue (up from 2.93% in 2014). In 1H16, revenue from retail business was RMB4,873 million, an Y-O-Y increase of 19%, which accounted for 3.87% of the overall revenue.. Sinopharm also owns 15 retail medical service flagship stores.</span></p>
<h6><a name="bookmark2"></a><span class="font2" style="font-weight:bold;"><a name="bookmark3"></a>Other services</span></h6>
<p><span class="font2">Other services include production and sale of pharmaceutical products, chemical reagents and laboratory supplies. It also actively engaged in innovation of pharmaceutical, medical sendees and other health-related industries to explore the synergistic development of its diversified business. This segment accounted for 2.06% of the group’s revenue i.e. RMB 4,361 million in 2015 and RMB 2,341 million in 1H16.</span></p>
<p><span class="font0" style="font-weight:bold;">19</span></p>
</body>
</html>